从事慢加急肝衰竭的临床和研究工作。工作主要集中在中国慢加急性肝衰竭临床大队列的研究以及通过肝脏病理、临床流行病学研究、独立危险因素分析、血浆多组学研究等全方位揭示慢加急肝衰竭的病理生理机制、中国临床流行病方面的疾病负担、发病及预后的独立危险因素以、通过多组学揭示的疾病特征和生物标记物。并通过转化形成具有自主知识产权的精准诊断试剂盒以及开展间充质干细胞治疗慢加急肝衰竭的探索性临床研究。 近五年发表的主要论文： 发表论文： 1. Yan Zhang,Wenting Tan, Xiaobo Wang… Yu Shi*, Hai Li*Investigation on the short‐term outcome and prognostic impact of predisposition, and precipitants in inpatients with chronic liver disease from Chinese AcuTe on CHronic LIver FailurE (CATCH‐LIFE) cohorts. September 2023Portal Hypertension & Cirrhosis 2(3). (主要通讯作者) 2. Yan Zhang, Wenting Tan, Xianbo Wang, Xin Zheng, Yan Huang, Beiling Li…Lining Guo*, Hai Li*. Metabolic biomarkers significantly enhance the prediction of HBV-related acute-onchronic liver failure prognosis.  Journal of Hepatology . 2023 Nov;79(5):1159-1171 (主要通讯作者)（IF=26.8） 3. Ju Zou , Hai Li  Guohong Deng … Yan Huang*, Ruochan Chen*. A novel prognostic nomogram for older patients with acute-on-chronic liver diseases (AoCLD): a nationwide, multicentre, prospective cohort study. Age Aging 2023 Jan 8;52(1):afac313 (并列第一作者)(IF=12.8) 4. Tongyu Wang, Wenting Tan, Xianbo Wang, Xin Zheng, Yan Huang  , Beiling Li ... Shi Yu*， Hai Li*. Role of precipitants on transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis. JHEP Rep. 2022 Jul 5;4(10):100529.  doi: 10.1016/j.jhepr.2022.100529. (主要通讯作者)（IF=9.9） 5. Mei X, Li H, Deng G, …, Ren H, Yuan W, Qian Z. Prevalence and clinical signifcance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China. Hepatology International. 2022 Feb;16(1):183-194. (并列第一作者) （IF=9.4） 6. Long L, Li H, Deng G, …, Mei X, Chen R, Huang Y. Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases. Frontiers in Medicine. 2021 Aug 2;8:709884(并列第一作者) （IF=5.02） 7. Ying Wang, Fuchen Dong, Shuning Sun, … Hai Li* and Zhongji Meng*. Increased INR Values Predict Accelerating Deterioration and High Short-Term Mortality Among Patients Hospitalized With Cirrhosis or Advanced Fibrosis. Front. Med. 2021;8:762291. doi: 10.3389/fmed.2021.762291(共同通讯作者) （IF=5.02） 8. Chen Y-y, Li H, Xu B-y, Zheng X, Li B,Wang X-b, Huang Y, Gao Y-h,Qian Z-p, Liu F, Lu X-b, Shang J, Li H, Wang S-y, Zhang Y-h, Meng Z-j* Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study. Front. Med. 2021;8:779744. doi: 10.3389/fmed.2021.779744 (并列第一作者) （IF=5.02） 9. Zhongji Meng, Tongyu Wang, Li Chen, Xinhe Chen, Longti Li, Xueqin Qin, Hai Li, Jie Luo. The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area. Current Topics in Medical Chemistry. 2021,21:920-927. (共同通讯作者) （IF=3.2） 10. Jing Liu, Hai Li , Jie Xia,… Xin Zheng. Baseline Neutrophil-to-Lymphocyte Ratio Is Independently Associated With 90-Day Transplant-Free Mortality in Patients With Cirrhosis. Front. Med. 8:726950. doi: 10.3389/fmed.2021.726950. (并列第一作者) （IF=5.02） 11. Li Han, Chenhui Ma, Huige Peng, Zhitao Wu, Huiming Xu, Jianjun Wu, Ning Zhang, Qinghui Jiang, Chen Ma, Ruimin Huang, Hai Li* and Guoyu Pan*. Define mesenchymal stem cell form its fate: Biodisposition of human mesenchymal stem cells in normal and Con-A induced liver injury mice. Journal of Pharmacology and Experimental Therapeuitcs, August 9, 2021, DOI: https://doi.org/10.1124/jpet.121.000607 （共同通讯作者）（IF=4.03，中科院药学杂志Q1) 12. Liang Qiao, Wenting Tan, Xiaobo Wang …Weituo Zhang*, Hai Li *. Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. Front. Med. 2021; 8:704452. doi: 10.3389/fmed.2021.704452 （主要通讯作者）（IF=5.02） 13. Liang Qiao,Xianbo Wang, Guohong Deng, Yan Huang, Jinjun Chen, Zhongji Meng, Xin Zheng, Yu Shi, Zhiping Qian, Feng Liu, Yanhang Gao Xiaobo Lu, Junping Liu, Wenyi Gu,Yan Zhang, Tongyu Wang, Dandan Wu, Fuchen Dong, Xin Sun*, Hai Li*. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure. (CATCH-LIFE) study. BMJ Open 2021;11: e037793. doi:10.1136/ （主要通讯作者）（IF=2.5） 14. Yan Zhang, Biao-yan Xu,Xian-bo Wang ….Hai Li*, Jing Hua*. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clinical Gastroenterology and Hepatology, 2020,18:2564-2572. (共同通讯作者)（IF=11.2） 授权及公开的国际、国家发明专利： 1. 已授权中国发明专利: 预测会否进展为ACLF 或者ACLF 患者会否死亡的生物标志物、 系统及其应用。发明人：李海，GUO,LINING,张艳（ 2. 已授权的美国发明专利: “Use of long-acting human recombinant soluble tumor necrosis factor-a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease.” patent number：US10，071，137 B2. 发明人：Hai Li 3. 已授权的美国发明专利：“Method of preventing acute or sub-acute hepatic failure in a subject by administering a soluble human tumor necrosis factor alpha fusion protein” patent number：US8，227，404 B2. 发明人：Hai Li 4. 已授权的美国发明专利：“Method of preventing acute or sub-acute hepatic failure by administering long-acting recombinant soluble tumor necrosis factor alpha receptor II fusion protein” patient number: US 8,575,088 B2 5. 已授权的中国发明专利： “长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途”。 专利号：ZL200619921014.5; 发明人：李海 6. 已授权的中国发明专利：“一种用于严重脓毒血症及急性肝衰竭的检测试剂盒”。专利号：201110073938.2，申请人：李海 7. 已公开的国际PCT 发明专利：WO 2007/041964 A1. “长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途”。申请人：李海